Jul 10, 2024
MLi-2 treatment of astrocytes
- 1Duke University
Document Citation: Shiyi Wang 2024. MLi-2 treatment of astrocytes. protocols.io https://dx.doi.org/10.17504/protocols.io.j8nlkwzzwl5r/v1
License: This is an open access document distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Created: May 23, 2023
Last Modified: July 10, 2024
Document Integer ID: 82325
Keywords: ASAPCRN
Funders Acknowledgement:
Aligning Science Across Parkinson’s (ASAP) initiative
Grant ID: ASAP-020607
Disclaimer
DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK
The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.
Abstract
LRRK2 inhibitor MLi-2 treatment of astrocytes
1. Cortical astrocytes were isolated from P0-P1 rat female pups as described in the “Cortical astrocyte isolation and culture” section.
2. Cultured astrocytes were treated with 0, 30, and 100 nM LRRK2 kinase inhibitor, MLi-2 (Tocris; Catalog number: 5756), for 72 hours.
3. Cultured astrocytes were lysed at DIV 11 for protein extraction and Western blot analysis.